一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Calderasib；Placebo；Pembrolizumab，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Calderasib；Placebo；Pembrolizumab · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Cancer Hospital ( Site 3136) · 合肥
- Beijing Cancer hospital ( Site 3133) · 北京
- Beijing Cancer hospital ( Site 3134) · 北京
- Beijing Peking Union Medical College Hospital-pneumology department ( Site 3102) · 北京
- Beijing Chest Hospital,Capital Medical University ( Site 3104) · 北京
- Chongqing University Cancer Hospital ( Site 3119) · 重庆
- Army Medical Center of People's Liberation Army ( Site 3142) · 重庆
- Fujian Cancer Hospital ( Site 3127) · 福州
- The First Affiliated hospital of Xiamen University ( Site 3148) · 厦门
- The First Affiliated Hospital of Guangzhou Medical University ( Site 3108) · 广州
- Southern Medical University Nanfang Hospital ( Site 3128) · 广州
- Sun Yat-sen University Cancer Center ( Site 3137) · 广州
- Harbin Medical University Cancer Hospital ( Site 3123) · 哈尔滨
- JIAMUSI TUBERCULOSIS HOSPITAL(CANCER HOSPITAL) ( Site 3124) · 佳木斯
- Henan Cancer Hospital ( Site 3149) · 郑州
- Tongji Hospital Tongji Medical,Science & Technology ( Site 3113) · 武汉
- Hubei Cancer Hospital ( Site 3126) · 武汉
- The Second Xiangya Hospital of Central South University ( Site 3130) · 长沙
- Hunan Cancer Hospital ( Site 3141) · 长沙
- Nanjing Gulou Hospital ( Site 3122) · 南京
- Nanjing First Hospital ( Site 3154) · 南京
- The First Affiliated Hospital of Soochow University ( Site 3146) · 苏州
- Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3155) · 无锡
- The Second Affiliated Hospital of Nanchang University ( Site 3139) · 南昌
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3138) · 南昌
- Jilin Province Tumor Hospital ( Site 3107) · 长春
- The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3150) · 西安
- Shandong Cancer Hospital ( Site 3116) · 济南
- LinYi Cancer Hospital ( Site 3111) · 临沂
- Shanghai Chest Hospital ( Site 3100) · 上海
- Fudan University Shanghai Cancer Center ( Site 3144) · 上海
- Zhongshan Hospital,Fudan University ( Site 3143) · 上海
- Shanxi Cancer Hospital ( Site 3131) · 太原
- The Second Affiliated Hospital of Air Force Medical University ( Site 3117) · 西安
- The Second Affiliated Hospital of Air Force Medical University ( Site 3152) · 西安
- West China Hospital, Sichuan University ( Site 3140) · 成都
- The Third People's Hospital of Chengdu (CDTPH) ( Site 3157) · 成都
- Sichuan Cancer hospital. ( Site 3109) · 成都
- The Second People's Hospital of Neijiang ( Site 3105) · 内江
- Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3101) · 乌鲁木齐
- Yunnan Province Cancer Hospital ( Site 3153) · 昆明
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115) · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3121) · 杭州
- Taizhou Hospital of Zhejiang Province ( Site 3145) · 临海
- The First Affiliated Hospital of Wenzhou Medical University ( Site 3151) · 温州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
- * Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8
- * Provides an archival tumor sample (≤5 years) or newly obtained core, incisional, or excisional biopsy or fine needle aspirate (FNA) of a tumor lesion, not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, programmed cell death ligand 1 (PD-L1) status, and biomarker research
- * If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to \< Grade 1 or baseline
- * If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART)
- * If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
- * If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06345729；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。